2024 年第 11 期 第 0 卷

血清脂质运载蛋白2和血管生成素样蛋白2水平与甲状腺乳头状癌患者病理参数及预后的关系

The relationship between serum lipocalin 2 and angiopoietin-like protein 2 levels and pathological parameters and prognosis of patients with papillary thyroid carcinoma

作者：阎靖芳1贾林梓1王军1闫峰2

英文作者：Yan Jingfang1 Jia Linzi1 Wang Jun1 Yan Feng2

单位：1山西省肿瘤医院中国医学科学院肿瘤医院山西医院山西医科大学附属肿瘤医院综合内科，太原030000；2山西省肿瘤医院中国医学科学院肿瘤医院山西医院山西医科大学附属肿瘤医院检验科，太原030000

英文单位：1Department of General Internal Medicine Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital Chinese Academy of Medical Sciences Cancer Hospital Affiliated to  Shanxi Medical University Taiyuan 030000 China; 2Department of Clinical Laboratory Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital Chinese Academy of Medical Sciences Cancer Hospital Affiliated to  Shanxi Medical University Taiyuan 030000 China

关键词：甲状腺乳头状癌；脂质运载蛋白2；血管生成素样蛋白2；疾病进展；预后

英文关键词：Papillarythyroidcarcinoma;Lipocalin2;Angiopoietin-likeprotein2;Diseaseprogression;Prognosis

• 摘要：

• 目的 探讨甲状腺乳头状癌（PTC）患者血清脂质运载蛋白2（LCN2）、血管生成素样蛋白2（ANGPTL2）与病理特征及预后的关系。方法 选取2017年1月至2020年6月山西省肿瘤医院收治的PTC患者83例为PTC组，另选取同期83例体检健康志愿者为对照组。采用酶联免疫吸附法检测血清LCN2、ANGPTL2水平。根据PTC患者血清LCN2、ANGPTL2水平均值分为高/低LCN2、ANGPTL2组，采用Kaplan-Meier法绘制高/低LCN2、ANGPTL2水平PTC患者无病生存曲线，采用Cox回归分析影响PTC患者预后的因素。结果 PTC组血清LCN2、ANGPTL2水平均高于对照组［（193±84）μg/L比（87±22）μg/L、（5.8±0.7）μg/L比（4.1±0.4）μg/L］（均P＜0.001）。PTC患者血清LCN2、ANGPTL2水平在不同TNM分期、淋巴结转移、远处转移患者中比较差异均有统计学意义（均P＜0.05）。83例PTC患者随访3年，3年无病生存率为77.1%（64/83）。Kaplan-Meier曲线分析显示，高LCN2组3年无病生存率低于低LCN2组，高ANGPTL2组3年无病生存率低于低ANGPTL2组（均P＜0.05）。多因素Cox回归分析结果显示，TNM分期Ⅲ～Ⅳ期、淋巴结转移、远处转移、LCN2升高、ANGPTL2升高为PTC患者预后不良的独立危险因素（均P＜0.05）。结论 PTC患者血清LCN2、ANGPTL2水平升高，与TNM分期、淋巴结转移、远处转移和预后密切相关，可能成为评估PTC疾病进展和预后新的标志物。

• Objective To investigate the relationship of serum lipocalin 2 (LCN2) and angiopoietin-like protein 2 (ANGPTL2) with pathological features and prognosis in patients with papillary thyroid carcinoma (PTC). Methods A total of 83 PTC patients admitted to Shanxi Province Cancer Hospital from January 2017 to June 2020 were selected as the PTC group, and 83 healthy volunteers were selected as the control group during the same period. The serum levels of LCN2 and ANGPTL2 were detected by enzyme-linked immunosorbent assay. According to the mean levels of serum LCN2 and ANGPTL2 in PTC patients, they were divided into high/low LCN2 and ANGPTL2 groups. The disease-free survival curves of PTC patients with high/low levels of LCN2 and ANGPTL2 were drawn by Kaplan-Meier method. The prognostic factors of PTC patients were analyzed by Cox regression.Results The serum levels of LCN2 and ANGPTL2 in PTC group were higher than those in control group ［（193±84）μg/L vs （87±22）μg/L, （5.8±0.7）μg/L vs （4.1±0.4）μg/L］(both P＜0.001). The serum levels of LCN2 and ANGPTL2 in PTC patients were significantly different in patients with different TNM stages, lymph node metastasis and distant metastasis (all P＜0.05). The 3-year disease-free survival rate of 83 patients with PTC was 77.1%(64/83). Kaplan-Meier curve analysis showed that the 3-year disease-free survival rate of the high LCN2 group was lower than that of the low LCN2 group, and the 3-year disease-free survival rate of the high ANGPTL2 group was lower than that of the low ANGPTL2 group (all P＜0.05). Multivariate Cox regression analysis showed that TNM stage Ⅲ to Ⅳ, lymph node metastasis, distant metastasis, elevated LCN2 and ANGPTL2 were independent risk factors for poor prognosis of PTC patients (all P<0.05). Conclusion The serum levels of LCN2 and ANGPTL2 in PTC patients are increased, which are closely related to TNM stage, lymph node metastasis, distant metastasis and prognosis, and may become new markers for evaluating the progression and prognosis of PTC.